Quinoline-based HIV Integrasc Inhibitors : The Development of Novel Inhibitors for the Treatment of HIV InfectionMUSIOL, Robert.Current pharmaceutical design (Print). 2013, Vol 19, Num 10, pp 1835-1849, issn 1381-6128, 15 p.Article

Effect of Food on the Pharmacokinetics of the Integrase Inhibitor DolutegravirSONG, Ivy; BORLAND, Julie; SHUGUANG CHEN et al.Antimicrobial agents and chemotherapy. 2012, Vol 56, Num 3, pp 1627-1629, issn 0066-4804, 3 p.Article

Pharmacokinetics and Bioavailability of an Integrase and Novel Pharmacoenhancer-Containing Single-Tablet Fixed-Dose Combination Regimen for the Treatment of H IVGERMAN, Polina; WARREN, David; WEST, Steve et al.Journal of acquired immune deficiency syndromes (1999). 2010, Vol 55, Num 3, pp 323-329, issn 1525-4135, 7 p.Article

Inhibition of Feline leukemia virus replication by the integrase inhibitor RaltegravirCATTORI, Valentino; WEIBEL, Beatrice; LUTZ, Hans et al.Veterinary microbiology (Amsterdam). 2011, Vol 152, Num 1-2, pp 165-168, issn 0378-1135, 4 p.Article

Dolutegravir: an exciting new kid on the blockAREVALO, Jose Luis Blanco; WHITLOCK, Gary George.Expert opinion on pharmacotherapy. 2014, Vol 15, Num 4, pp 573-582, issn 1465-6566, 10 p.Article

Inter- and intra-patient variability of raltegravir pharmacokinetics in HIV-1-infected subjectsCATTANEO, Dario; GERVASONI, Cristina; MERAVIGLIA, Paola et al.Journal of antimicrobial chemotherapy (Print). 2012, Vol 67, Num 2, pp 460-464, issn 0305-7453, 5 p.Article

Raltegravir as antiretroviral therapy in HIV/AIDSSHARMA, Malika; WALMSLEY, Sharon L.Expert opinion on pharmacotherapy. 2014, Vol 15, Num 3, pp 395-405, issn 1465-6566, 11 p.Article

Overcoming Resistance to Existing Therapies in HIV-Infected Patients : The Role of New Antiretroviral DrugsPERNO, Carlo-Federico; MOYLE, Graeme; TSOUKAS, Chris et al.Journal of medical virology. 2008, Vol 80, Num 4, pp 565-576, issn 0146-6615, 12 p.Article

Integrase Inhibitors Effective against Human T-Cell Leukemia Virus Type 1MUHAMMAD ESA SEEGULAML; RATNER, Lee.Antimicrobial agents and chemotherapy. 2011, Vol 55, Num 5, pp 2011-2017, issn 0066-4804, 7 p.Article

Selection of the Q148R integrase inhibitor resistance mutation in a failing raltegravir containing regimenROQUEBERT, Benedicte; BLUM, Laurent; COLLIN, Gilles et al.AIDS (London). 2008, Vol 22, Num 15, pp 2045-2046, issn 0269-9370, 2 p.Article

Exacerbation of depression associated with starting raltegravir : a report of four casesHARRIS, Marianne; LARSEN, Gerene; MONTANER, Julio S. G et al.AIDS (London). 2008, Vol 22, Num 14, pp 1890-1892, issn 0269-9370, 3 p.Article

Clinical Pharmacokinetic and Pharmacodynamic Profile of the HIV Integrase Inhibitor ElvitegravirRAMANATHAN, Srinivasan; MATHIAS, Anita A; GERMAN, Polina et al.Clinical pharmacokinetics. 2011, Vol 50, Num 4, pp 229-244, issn 0312-5963, 16 p.Article

Raltegravir-induced cerebellar ataxiaREISS, Kim A; BAILEY, Justin R; PHAM, Paul A et al.AIDS (London). 2010, Vol 24, Num 17, issn 0269-9370, p. 2757Article

Secondary mutations in viruses resistant to HIV-1 integrase inhibitors that restore viral infectivity and replication kineticsNAKAHARA, Koichiro; WAKASA-MORIMOTO, Chiaki; YOSHINAGA, Tomokazu et al.Antiviral research. 2009, Vol 81, Num 2, pp 141-146, issn 0166-3542, 6 p.Article

Determination of the HIV integrase inhibitor, MK-0518 (raltegravir), in human plasma using 96-well liquid-liquid extraction and HPLC-MS/MSMERSCHMAN, S. A; VALLANO, P. T; WENNING, L. A et al.Journal of chromatography. B. 2007, Vol 857, Num 1, pp 15-24, issn 1570-0232, 10 p.Article

Design, synthesis, molecular modeling, and anti-HIV-1 integrase activity of a series of photoactivatable diketo acid-containing inhibitors as affinity probesSECHI, Mario; CARTA, Fabrizio; SANNIA, Luciano et al.Antiviral research. 2009, Vol 81, Num 3, pp 267-276, issn 0166-3542, 10 p.Article

Dolutegravir: A New Integrase Strand Transfer Inhibitor for the Treatment of HIVSHAH, Bhavik M; SCHAFER, Jason J; DESIMONE, Joseph A et al.Pharmacotherapy. 2014, Vol 34, Num 5, pp 506-520, issn 0277-0008, 15 p.Article

Elvitegravir overcomes resistance to raltegravir induced by integrase mutation Y143METIFIOT, Mathieu; VANDEGRAAFF, Nick; MADDALI, Kasthuraiah et al.AIDS (London). 2011, Vol 25, Num 9, pp 1175-1178, issn 0269-9370, 4 p.Article

Integrase Inhibitors: A Novel Class of Antiretroviral AgentsSCHAFER, Jason J; SQUIRES, Kathleen E.The Annals of pharmacotherapy. 2010, Vol 44, Num 1, pp 145-156, issn 1060-0280, 12 p.Article

Dolutegravir, a Second-Generation Integrase Inhibitor for the Treatment of HIV-1 InfectionRATHBUN, R. Chris; LOCKHART, Staci M; MILLER, Misty M et al.The Annals of pharmacotherapy. 2014, Vol 48, Num 3, pp 395-403, issn 1060-0280, 9 p.Article

Antiviral effect of raltegravir on HTLV-1 carriersTREVINO, Ana; PARRA, Patricia; BAR-MAGEN, Tamara et al.Journal of antimicrobial chemotherapy (Print). 2012, Vol 67, Num 1, pp 218-221, issn 0305-7453, 4 p.Article

Update on Raltegravir and the Development of New Integrase Strand Transfer InhibitorsLEE SHAMROE, Caitlin; BOOKSTAVER, Paul Brandon; ROKAS, Kristina E. E et al.Southern medical journal (Birmingham, Ala. Print). 2012, Vol 105, Num 7, pp 370-378, issn 0038-4348, 9 p.Article

Effect of continuous venovenous hemodiafiltration on darunavir and raltegravir exposure after administration via a gastroduodenal tubeTAEGTMEYER, Anne B; MÜLLER, Veronique; KOVARI, Helen et al.AIDS (London). 2011, Vol 25, Num 10, pp 1339-1341, issn 0269-9370, 3 p.Article

Cross-resistance Profile of the Novel Integrase Inhibitor Dolutegravir (S/GSK1349572) Using Clonal Viral Variants Selected in Patients Failing RaltegravirCANDUCCI, Filippo; CERESOLA, Elisa R; BOERI, Enzo et al.The Journal of infectious diseases. 2011, Vol 204, Num 11, pp 1811-1815, issn 0022-1899, 5 p.Article

Raltegravir Penetration in Seminal Plasma of Healthy VolunteersCALCAGNO, Andrea; BONORA, Stefano; D'AVOLIO, Antonio et al.Antimicrobial agents and chemotherapy. 2010, Vol 54, Num 6, pp 2744-2745, issn 0066-4804, 2 p.Article